Military Academy

About: Military Academy is a based out in . It is known for research contribution in the topics: Population & Fuzzy logic. The organization has 2478 authors who have published 3003 publications receiving 33188 citations.

The concept of document warehousing for multi-dimensional modeling of textual-based business intelligence

Abstract: During the past decade, data warehousing has been widely adopted in the business community. It provides multi-dimensional analyses on cumulated historical business data for helping contemporary administrative decision-making. Nevertheless, it is believed that only about 20% information can be extracted from data warehouses concerning numeric data only, the other 80% information is hidden in non-numeric data or even in documents. Therefore, many researchers now advocate that it is time to conduct research work on document warehousing to capture complete business intelligence. Document warehouses, unlike traditional document management systems, include extensive semantic information about documents, cross-document feature relations, and document grouping or clustering to provide a more accurate and more efficient access to text-oriented business intelligence. In this paper, we discuss the basic concept of document warehousing and present its formal definitions. Then, we propose a general system framework and elaborate some useful applications to illustrate the importance of document warehousing. The work is essential for establishing an infrastructure to help combine text processing with numeric OLAP processing technologies. The combination of data warehousing and document warehousing will be one of the most important kernels of knowledge management and customer relationship management applications.

Increased muscle volume and strength following six days of low-intensity resistance training with restricted muscle blood flow

Abstract: Traditional high-intensity resistance training performed 2-3 times per week induces muscle hypertrophy, at least, in 5 weeks (i.e. 10-15 training sessions). To examine the effect of a higher training frequency (12 sessions in 6 days), healthy young men performed low-intensity resistance training with (n=8, LIT-BFR) and without (n=8, LIT-CON) leg blood flow restriction with cuff inflation (BFR) twice per day for 6 days. Training involved 4 sets of knee extension exercise (75 total contractions) at 20% 1-RM. Significant muscle hypertrophy was observed only in the LIT-BFR group as estimated muscle-bone cross-sectional area (CSA) (2.4%), MRI-measured mid-thigh quadriceps muscle CSA (3.5%) and quadriceps muscle volume (3.0%) increased. The resulting hypertrophic potential (% change in muscle size divided by number of training sessions; ∼0.3% per session) is similar to previously reported traditional high-intensity training (0.1 to 0.5% per session). Improved 1-RM knee extension strength (6.7%) following LIT-BFR training was accounted for by increased muscle mass as relative strength (1-RM/CSA) did not change. There was no apparent muscle damage associated with the exercise training as blood levels of creatine kinase, myoglobin, and interleukin-6 remained unchanged throughout the training period in both training groups. A single bout of training exercise with and without BFR produced no signs of blood clotting as plasma thrombin-antithrombin complex, prothrombin fragment 1,2 and D-dimer were unchanged. In conclusion, changes in muscle mass and strength following 6-day (12 sessions) of low-intensity resistance training requires BFR to produce responses comparable to the effect of several weeks of high-intensity resistance training.

Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial.

Abstract: Objective To assess the safety, tolerability, and efficacy of spliceosomal peptide P140 (IPP-201101; sequence 131–151 of the U1-70K protein phosphorylated at Ser140), which is recognized by lupus CD4+ T cells, in the treatment of patients with systemic lupus erythematosus (SLE). Methods An open-label, dose-escalation phase II study was conducted in two centers in Bulgaria. Twenty patients (2 male and 18 female) with moderately active SLE received 3 subcutaneous (SC) administrations of a clinical batch of P140 peptide at 2-week intervals. Clinical evaluation was performed using approved scales. A panel of autoantibodies, including antinuclear antibodies, antibodies to extractable nuclear antigens (U1 RNP, SmD1, Ro/SSA, La/SSB), and antibodies to double-stranded DNA (anti-dsDNA), chromatin, cardiolipin, and peptides of the U1-70K protein, was tested by enzyme-linked immunosorbent assay (ELISA). The plasma levels of C-reactive protein, total Ig, IgG, IgG subclasses, IgM, IgA, and IgE, and of the cytokines interleukin-2 and tumor necrosis factor α were measured by ELISA and nephelometry. Results IgG anti-dsDNA antibody levels decreased by at least 20% in 7 of 10 patients who received 3 × 200 μg IPP-201101 (group 1), but only in 1 patient in the group receiving 3 × 1,000 μg IPP-201101 (group 2). Physician's global assessment of disease activity scores and scores on the SLE Disease Activity Index were significantly decreased in group 1. The changes occurred progressively in the population of responders, increased in magnitude during the treatment period, and were sustained. No clinical or biologic adverse effects were observed in the individuals, except for some local irritation at the highest concentration. Conclusion IPP-201101 was found to be safe and well tolerated by subjects. Three SC doses of IPP-201101 at 200 μg significantly improved the clinical and biologic status of lupus patients.